Neumora Therapeutics (NMRA) Research & Development (2022 - 2026)

Neumora Therapeutics' Research & Development history runs 5 years deep, the most recent figure standing at $38.6 million for Q1 2026.

• On a quarterly basis, Research & Development fell 25.99% year-over-year to $38.6 million in Q1 2026; TTM through Mar 2026 was $162.5 million, a 21.61% decrease from a year earlier, with the FY2025 full-year figure at $176.1 million, down 12.37% from the prior year.
• Research & Development fell to $38.6 million in Q1 2026 per NMRA's latest filing, from $44.7 million in the prior quarter.
• Across five years, Research & Development topped out at $60.6 million in Q3 2024 and bottomed at $22.5 million in Q3 2022.
• The 5-year median for Research & Development is $40.5 million (2025), against an average of $40.3 million.
• Across the five-year window, Research & Development jumped 84.49% in 2023 and slumped 33.17% in 2025, its largest moves.
• Year by year, Research & Development stood at $23.5 million in 2022, then surged by 65.22% to $38.9 million in 2023, then grew by 18.14% to $45.9 million in 2024, then slipped by 2.71% to $44.7 million in 2025, then dropped by 13.59% to $38.6 million in 2026.
• Per Business Quant, the three latest NMRA Research & Development figures stand at $38.6 million (Q1 2026), $44.7 million (Q4 2025), and $40.5 million (Q3 2025).